A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
Price : $35 *
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TYPHER
- 31 Aug 2018 Biomarkers information updated
- 06 Jun 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified June 2016).
- 16 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClnicalTrials.gov record.